Patents by Inventor Ronald G. Lafreniere

Ronald G. Lafreniere has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acids encoding sodium channel SCN1A alpha subunit proteins and mutations associated with epilepsy
    Patent number: 8143005
    Abstract: The present invention relates to epilepsy. More particularly, the present invention relates to idiopathic generalized epilepsy (IGE) and to the identification of three genes mapping to chromosome 2, which show mutations in patients with epilepsy. The invention further relates to nucleic acid sequences, and protein sequences of these loci (SCNA) and to the use thereof to assess, diagnose, prognose or treat epilepsy, to predict an epileptic individual's response to medication and to identify agents which modulate the function of the SCNA. The invention also provides screening assays using SCN1A, SCN2A and/or SCN3A which can identify compounds which have therapeutic benefit for epilepsy and related neurological disorders.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: March 27, 2012
    Assignee: McGill University
    Inventors: Guy A. Rouleau, Ronald G. Lafrenière, Daniel Rochefort
  • Nucleic acid encoding sodium channel SCN3A alpha subunits
    Patent number: 7951931
    Abstract: The present invention relates to epilepsy. More particularly, the present invention relates to idiopathic generalized epilepsy (IGE) and to the identification of three genes mapping to chromosome 2, which show mutations in patients with epilepsy. The invention further relates to nucleic acid sequences, and protein sequences of these loci (SCNA) and to the use thereof to assess, diagnose, prognose or treat epilepsy, to predict an epileptic individual's response to medication and to identify agents which modulate the function of the SCNA. The invention also provides screening assays using SCN1A, SCN2A and/or SCN3A which can identify compounds which have therapeutic benefit for epilepsy and related neurological disorders.
    Type: Grant
    Filed: February 2, 2009
    Date of Patent: May 31, 2011
    Assignee: McGill University
    Inventors: Guy A. Rouleau, Ronald G. Lafrenière, Daniel Rochefort
  • NUCLEIC ACIDS ENCODING SODIUM CHANNEL SCN1A ALPHA SUBUNIT PROTEINS AND MUTATIONS ASSOCIATED WITH EPILEPSY
    Publication number: 20100092990
    Abstract: The present invention relates to epilepsy. More particularly, the present invention relates to idiopathic generalized epilepsy (IGE) and to the identification of three genes mapping to chromosome 2, which show mutations in patients with epilepsy. The invention further relates to nucleic acid sequences, and protein sequences of these loci (SCNA) and to the use thereof to assess, diagnose, prognose or treat epilepsy, to predict an epileptic individual's response to medication and to identify agents which modulate the function of the SCNA. The invention also provides screening assays using SCN1A, SCN2A and/or SCN3A which can identify compounds which have therapeutic benefit for epilepsy and related neurological disorders.
    Type: Application
    Filed: December 14, 2009
    Publication date: April 15, 2010
    Inventors: Guy A. ROULEAU, Ronald G. Lafreniére, Daniel Rochefort
  • Nucleic acids encoding sodium channel SCN1A alpha subunit proteins with mutations associated with epilepsy
    Patent number: 7655460
    Abstract: The present invention relates to epilepsy. More particularly, the present invention relates to idiopathic generalized epilepsy (IGE) and to the identification of three genes mapping to chromosome 2, which show mutations in patients with epilepsy. The invention further relates to nucleic acid sequences, and protein sequences of these loci (SCNA) and to the use thereof to assess, diagnose, prognose or treat epilepsy, to predict an epileptic individual's response to medication and to identify agents which modulate the function of the SCNA. The invention also provides screening assays using SCN1A, SCN2A and/or SCN3A which can identify compounds which have therapeutic benefit for epilepsy and related neurological disorders.
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: February 2, 2010
    Assignee: McGill University
    Inventors: Guy A. Rouleau, Ronald G. Lafrenière, Daniel Rochefort
  • NUCLEIC ACID ENCODING OR TARGETING SODIUM CHANNEL SCN3A ALPHA SUBUNITS
    Publication number: 20090148855
    Abstract: The present invention relates to epilepsy. More particularly, the present invention relates to idiopathic generalized epilepsy (IGE) and to the identification of three genes mapping to chromosome 2, which show mutations in patients with epilepsy. The invention further relates to nucleic acid sequences, and protein sequences of these loci (SCNA) and to the use thereof to assess, diagnose, prognose or treat epilepsy, to predict an epileptic individual's response to medication and to identify agents which modulate the function of the SCNA. The invention also provides screening assays using SCN1A, SCN2A and/or SCN3A which can identify compounds which have therapeutic benefit for epilepsy and related neurological disorders.
    Type: Application
    Filed: February 2, 2009
    Publication date: June 11, 2009
    Inventors: Guy A. ROULEAU, Ronald G. LAFRENIERE, Daniel ROCHEFORT
  • SCN3A locus for idiopathic generalized epilepsy, mutations thereof and method using same
    Patent number: 7528093
    Abstract: The present invention relates to epilepsy. More particularly, the present invention relates to idiopathic generalized epilepsy (IGE) and to the identification of three genes mapping to chromosome 2, which show mutations in patients with epilepsy. The invention further relates to nucleic acid sequences, and protein sequences of these loci (SCNA) and to the use thereof to assess, diagnose, prognose or treat epilepsy, to predict an epileptic individual's response to medication and to identify agents which modulate the function of the SCNA. The invention also provides screening assays using SCN1A, SCN2A and/or SCN3A which can identify compounds which have therapeutic benefit for epilepsy and related neurological disorders.
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: May 5, 2009
    Inventors: Guy A Rouleau, Ronald G. Lafreniere, Daniel Rochefort, Patrick Cossette, David Ragsdale
  • Nucleic acids encoding sodium channel scn3a alpha subunits
    Patent number: 7485449
    Abstract: The present invention relates to epilepsy. More particularly, the present invention relates to idiopathic generalized epilepsy (IGE) and to the identification of three genes mapping to chromosome 2, which show mutations in patients with epilepsy. The invention further relates to nucleic acid sequences, and protein sequences of these loci (SCNA) and to the use thereof to assess, diagnose, prognose or treat epilepsy, to predict an epileptic individual's response to medication and to identify agents which modulate the function of the SCNA. The invention also provides screening assays using SCN1A, SCN2A and/or SCN3A which can identify compounds which have therapeutic benefit for epilepsy and related neurological disorders.
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: February 3, 2009
    Assignee: McGill University
    Inventors: Guy A. Rouleau, Ronald G. Lafrenière, Daniel Rochefort
  • Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
    Publication number: 20040214195
    Abstract: The present invention relates to epilepsy. More particularly, the present invention relates to idiopathic generalized epilepsy (IGE) and to the identification of three genes mapping to chromosome 2, which show mutations in patients with epilepsy. The invention further relates to nucleic acid sequences, and protein sequences of these loci (SCNA) and to the use thereof to assess, diagnose, prognose or treat epilepsy, to predict an epileptic individual's response to medication and to identify agents which modulate the function of the SCNA. The invention also provides screening assays using SCN1A, SCN2A and/or SCN3A which can identify compounds which have therapeutic benefit for epilepsy and related neurological disorders.
    Type: Application
    Filed: September 17, 2003
    Publication date: October 28, 2004
    Inventors: Guy A. Rouleau, Ronald G. Lafreniere, Daniel Rochefort
  • Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
    Publication number: 20040096885
    Abstract: The present invention relates to epilepsy. More particularly, the present invention relates to idiopathic generalized epilepsy (IGE) and to the identification of three genes mapping to chromosome 2, which show mutations in patients with epilepsy. The invention further relates to nucleic acid sequences, and protein sequences of these loci (SCNA) and to the use thereof to assess, diagnose, prognose or treat epilepsy, to predict an epileptic individual's response to medication and to identify agents which modulate the function of the SCNA. The invention also provides screening assays using SCN1A, SCN2A and/or SCN3A which can identify compounds which have therapeutic benefit for epilepsy and related neurological disorders.
    Type: Application
    Filed: September 17, 2003
    Publication date: May 20, 2004
    Inventors: Guy A. Rouleau, Ronald G. Lafreniere, Daniel Rochefort
  • Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
    Publication number: 20040096886
    Abstract: The present invention relates to epilepsy. More particularly, the present invention relates to idiopathic generalized epilepsy (IGE) and to the identification of three genes mapping to chromosome 2, which show mutations in patients with epilepsy. The invention further relates to nucleic acid sequences, and protein sequences of these loci (SCNA) and to the use thereof to assess, diagnose, prognose or treat epilepsy, to predict an epileptic individual's response to medication and to identify agents which modulate the function of the SCNA. The invention also provides screening assays using SCN1A, SCN2A and/or SCN3A which can identify compounds which have therapeutic benefit for epilepsy and related neurological disorders.
    Type: Application
    Filed: September 17, 2003
    Publication date: May 20, 2004
    Inventors: Guy A. Rouleau, Ronald G. Lafreniere, Daniel Rochefort